Quinazolin-oxime derivatives as Hsp90 inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8592430
APP PUB NO 20110118258A1
SERIAL NO

12599116

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • DAC SLR;DAC SRL

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Barker, Oliver Robin Oxfordshire, GB 1 2
Courtney, Stephen Martin Oxfordshire, GB 57 754
Gardiner, Mihaly Daniel Oxfordshire, GB 1 2
Hesterkamp, Thomas Hamburg, DE 8 35
Mather, Owen Clifford Oxfordshire, GB 1 2
Montalbetti, Christian Aldo Georges Napoleon Oxfordshire, GB 1 2
Whittaker, Mark Oxfordshire, GB 81 692
Yarnold, Christopher John Oxfordshire, GB 18 96

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 26, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00